TrialMuscle & nerve2026

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.

Angela Genge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.